Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628761 | 0.87 | TRPM8 (0.58) | TRPM8EPHX1P2RX4ALDH1A1HPGD | |
| SCHEMBL4812089 | 0.87 | P2RX4 (0.61) | TRPM8EPHX1P2RX4KCNA5ALDH1A1 | |
| SCHEMBL5400523 | 0.87 | TRPM8 (0.53) | TRPM8EPHX1P2RX4KCNA5ALDH1A1 | |
| SCHEMBL2628771 | 0.86 | TRPM8 (0.57) | TRPM8EPHX1P2RX4ALDH1A1TRPV1 | |
| SCHEMBL4141645 | 0.85 | TRPM8 (0.57) | TRPM8EPHX1P2RX4KCNA5ALDH1A1 | |
| SCHEMBL4912015 | 0.85 | TRPM8 (0.56) | TRPM8EPHX1P2RX4KCNA5ALDH1A1 | |
| SCHEMBL28946956 | 0.85 | TRPM8 (0.56) | TRPM8EPHX1P2RX4ALDH1A1 | |
| SCHEMBL4883688 | 0.85 | TRPM8 (0.56) | TRPM8EPHX1P2RX4KCNA5ALDH1A1 | |
| SCHEMBL4820315 | 0.84 | TRPM8 (0.55) | TRPM8EPHX1P2RX4ALDH1A1 | |
| SCHEMBL4963208 | 0.84 | TRPM8 (0.64) | TRPM8EPHX1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 10/4885EPHX1 2902/4885P2RX4 223/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 8/4885EPHX1 2270/4885P2RX4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.